Mechanistic description
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
Mechanism / pathway
- VEGF-
- neurodegeneration
Evidence for (1)
The proposed priority experiment is concrete: spatial transcriptomics plus vascular imaging ordered against amyloid and tau burden across hippocampal subfields
Evidence against (1)
Therapeutic tractability is not established by the current source evidence.
Evidence matrix
Supporting
- The proposed priority experiment is concrete: spatial transcriptomics plus vascular imaging ordered against amyloid and tau burden across hippocampal subfields 10.1002/alz.14419
Contradicting
- Therapeutic tractability is not established by the current source evidence. 10.1002/alz.14419
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund signals
from 2 contributing personas in log-odds space, weighted
by uniform. Prior 50%.
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Perturbation-first validation should precede therapeutic claims for VEGF Family…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-e128d575e8
@misc{scidex_hypothesis_he128d57,
title = {Perturbation-first validation should precede therapeutic claims for VEGF Family…},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-e128d575e8},
note = {SciDEX artifact hypothesis:h-e128d575e8}
}